Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Jun 20, 2013
WOODCLIFF LAKE, NJ and SAN DIEGO, CA, June 20, 2013 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc., (NASDAQ:ARNA) announced today that data from the BELVIQ® (lorcaserin HCl) Phase 3 clinical trial program will be presented at the following scientific meeting: American Diabetes Association's 73rd Scientific SessionsChicago: J...
Jun 14, 2013
WOODCLIFF LAKE, N.J. and SAN DIEGO, June 14, 2013 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), announced today that data from the BELVIQ® (lorcaserin HCl) Phase 3 clinical trial program will be presented at the following scientific meeting: ENDO 2013, the Endocrine Society's 95th Annual Meeting & ExpoSan Fr...
Jun 14, 2013
SAN DIEGO, June 14, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the 2013 Wells Fargo Securities Healthcare Conference on Wednesday, June 19, 2013, at 2:25 p.m. Eastern Time (11:25 a.m. Pacific Time), at the InterContinental Hotel in Boston, Massachu...
Jun 7, 2013
SAN DIEGO, June 7, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) reported today on the launch of BELVIQ (pronounced BEL-VEEK) in the United States. BELVIQ will be available to patients by prescription in US pharmacies beginning June 11. Eisai Inc. is responsible for the marketing and distribution of BELVIQ under its agreement with...
May 24, 2013
SAN DIEGO, May 24, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the following investor conferences: Deutsche Bank Securities 38th Annual Health Care ConferencePresentation: May 30, 2013, at 12:00 p.m. Eastern Time (9:00 a.m. Pacific Time) ...
May 10, 2013
SAN DIEGO, May 10, 2013  /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, May 15, 2013, at 2:20 p.m. Pacific Time (5:20 p.m. Eastern Time), at the Encore at the Wynn Las Vegas Hotel i...
May 7, 2013
SAN DIEGO, May 7, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the Office of the Federal Register filed for public inspection the US Drug Enforcement Administration's (DEA) final rule placing BELVIQ (pronounced BEL-VEEK) into Schedule IV of the Controlled Substances Act. The scheduling designation will be eff...
May 2, 2013
SAN DIEGO, May 2, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reported financial results for the first quarter ended March 31, 2013. Recent Developments: BELVIQ® (lorcaserin HCl) The American Association of Clinical Endocrinologists (AACE) published it...
Apr 26, 2013
SAN DIEGO, April 26, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that it will provide a corporate update and discuss first quarter 2013 financial results after the NASDAQ Global Select Market closes on Thursday, May 2, 2013. The conference call and webcast will begin at 5:15 p.m. Eastern Time (2:15 p.m. Pacific T...
Apr 5, 2013
SAN DIEGO, April 5, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the initiation of dosing in a Phase 1 clinical trial of APD334, a novel oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor for the potential treatment of autoimmune diseases. This randomized, double-blind an...
Apr 1, 2013
SAN DIEGO, April 1, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Eisai Laboratorios S. de R.L. de C.V., a subsidiary of Eisai Inc., has submitted a marketing authorization application (MAA) for BELVIQ® (lorcaserin HCl) in Mexico with the Federal Commission for the Protection Against Sanitary Risk (COFEPR...
Mar 4, 2013
SAN DIEGO, March 4, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today provided a corporate update and reviewed financial results for the fourth quarter and full year ended December 31, 2012. "2012 was a momentous year for Arena with the FDA approval of our first drug, BELVIQ," said Jack Lief, Arena's President and Chief E...
Feb 27, 2013
SAN DIEGO, Feb. 27, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the Cowen and Company 33rd Annual Health Care Conference on Wednesday, March 6, 2013, at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time), at The Boston Marriott Copley Place in Boston,...
Feb 25, 2013
SAN DIEGO, Feb. 25, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that it will host a conference call and webcast to provide a corporate update and discuss fourth quarter and full year 2012 financial results before the NASDAQ Global Select Market opens on Monday, March 4, 2013. The conference call and webcast will ...
Feb 6, 2013
SAN DIEGO, Feb. 6, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at two upcoming investor conferences at The Waldorf Astoria in New York City: 15th Annual BIO CEO & Investor ConferencePresentation: February 12, 2013, at 1:30 p.m. Eastern Time ...
= add release to Briefcase